Ki67 index in intracranial ependymoma: A promising histopathological candidate biomarker

Histopathology

Volumn 53, Issue 1, 2008, Pages 39-47

  Preusser, M ^a   Heinzl, H ^b   Gelpi, E ^a   Hoftberger R ^a   Fischer, I ^a   Pipp, I ^a   Milenkovic, I ^a   Wohrer A ^a   Popovici, F ^a   Wolfsberger, S ^b   Hainfellner, J A ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ependymoma; Immunohistochemistry; Ki67 index; Observer agreement; Prognosis

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; EPENDYMOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRACRANIAL TUMOR; OBSERVATIONAL METHOD; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CELL COUNT; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 45549094602     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03065.x     Document Type: Article

References (35)

1. McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng HK. Ependymoma. In Kleihues P, Cavanee WK eds. World Health Organisation classification of tumours of the nervous system. Lyon:IARC Press, 2007 74 78.
2. McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng HK. Anaplastic ependymoma. In Kleihues P, Cavanee WK eds. World Health Organisation classification of tumours of the nervous system. Lyon:IARC Press, 2007 79 80.
3. Peris-Bonet R, Martinez-Garcia C, Lacour B et al. Childhood central nervous system tumours - incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. Eur. J. Cancer 2006 42 2064 2080.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. Lyon:IARC Press, 2007.
5. Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo A. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr. Neurosurg. 1998 28 135 142.
6. Paulino AC, Wen BC, Buatti JM et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am. J. Clin. Oncol. 2002 25 117 122.
7. Mansur DB, Perry A, Rajaram V et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int. J. Radiat. Oncol. Biol. Phys. 2005 61 387 391.
8. Wolfsberger S, Fischer I, Hoftberger R et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am. J. Surg. Pathol. 2004 28 914 920.
9. Zamecnik J, Snuderl M, Eckschlager T et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod. Pathol. 2003 16 980 991.
10. Reni M, Brandes AA, Vavassori V et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004 100 1221 1229.
11. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N. Long-term outcome in patients harboring intracranial ependymoma. J. Neurosurg. 2005 103 31 37.
12. Merchant TE, Jenkins JJ, Burger PC et al. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int. J. Radiat. Oncol. Biol. Phys. 2002 53 52 57.
13. Guyotat J, Signorelli F, Desme S et al. Intracranial ependymomas in adult patients: analyses of prognostic factors. J. Neurooncol. 2002 60 255 268.
14. Ernestus RI, Schroder R, Stutzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br. J. Neurosurg. 1997 11 421 428.
15. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J. Neurosurg. 1989 70 31 36.
16. Foreman NK, Love S, Thorne R. Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr. Neurosurg. 1996 24 119 125.
17. Schiffer D, Giordana MT. Prognosis of ependymoma. Childs Nerv. Syst. 1998 14 357 361.
18. Grill J, Pascal C, Chantal K. Childhood ependymoma: a systematic review of treatment options and strategies. Paediatr. Drugs 2003 5 533 543.
19. Bennetto L, Foreman N, Harding B et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol. Appl. Neurobiol. 1998 24 434 440.
20. Figarella-Branger D, Civatte M, Bouvier-Labit C et al. Prognostic factors in intracranial ependymomas in children. J. Neurosurg. 2000 93 605 613.
21. Kurt E, Zheng PP, Hop WC et al. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 2006 106 388 395.
22. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer 2006 6 565 571.
23. Kleihues P, Cavanee WK. WHO Classification of tumours of the central nervous system. Lyon:IARC Press, 2007.
24. Hsu CY, Ho DM, Yang CF, Chiang H. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod. Pathol. 2003 16 951 957.
25. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989 45 255 268.
26. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 1999 8 135 160.
27. Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C. Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl. Immunohistochem. Mol. Morphol. 2006 14 109 114.
28. Kayser G, Radziszowski D, Bzdyl P, Sommer R, Kayser K. Theory and implementation of an electronic, automated measurement system for images obtained from immunohistochemically stained slides. Anal. Quant. Cytol. Histol. 2006 28 27 38.
29. Law AK, Lam KY, Lam FK, Wong TK, Poon JL, Chan FH. Image analysis system for assessment of immunohistochemically stained proliferative marker (MIB-1) in oesophageal squamous cell carcinoma. Comput. Methods Programs Biomed. 2003 70 37 45.
30. Hasegawa T, Yamamoto S, Matsuno Y. Quantitative immunohistochemical evaluation of MIB-1 labeling index in adult soft-tissue sarcomas by computer-assisted image analysis. Pathol. Int. 2002 52 433 437.
31. Prayson RA. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv. Anat. Pathol. 2005 12 144 148.
32. Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas. Ann. Diagn. Pathol. 2003 7 9 13.
33. Grzybicki DM, Liu Y, Moore SA et al. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 2001 92 2720 2726.
34. Wiestler OD, Schiffer D, Coons SW, Prayson RA, Rosenblum MK. Ependymoma. In Kleihues P, Cavanee WK eds. World Health Organisation classification of tumours: pathology and genetics of tumours of the nervous syste. Lyon:IARC Press, 2000 72 76.
35. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J. Pathol. 2002 198 292 299.